journal article·2025-06-04Open access

Core–Shell ZnO2@Cerium-Based Metal–Organic Framework with Low Turnover, Dual-Catalytic Activity for Biosafe Biofilm Dispersal and Immune Modulation

Renfei Wu, Tianjin Ge, Tianrong Yu, Qiaolan Shi, Rui Shi, Yijin Ren, Henk J. Busscher, Jian Liu, Henny C. van der Mei

ACS Applied Materials & Interfaces· Volume 17· Issue 22

Abstract

High Resolution Image Download MS PowerPoint Slide The era of relying on antibiotics for curing bacterial infections is rapidly approaching an end, necessitating development of non-antibiotic-based infection-control strategies. Dispersal of infectious biofilms is a potential strategy but yields dispersed bacteria in blood that may cause sepsis. We report a bromide-loaded, core–shell ZnO 2 -nanoparticle/Ce-based metal–organic framework (ZnO 2 @CeMOF/Br) of which the ZnO 2 core degrades at pH ≤ 6.5, leaving the MOF’s Ce node intact. ZnO 2 -core degradation initially generates a nonradical, relatively stable, low-oxidative hydrogen peroxide that can cleave matrix DNA causing dispersal of Staphylococcus aureus biofilms and reacts with bromide ions to form transient hypobromous acid. Hypobromous acid modulates macrophage polarization toward an M1-like phenotype to clear dispersed bacteria from blood. Subsequently the Ce 3+ /Ce 4+ redox couple forming the Ce node acts as an electron shuttle upon oxidation/reduction to faciltate two catalytic reactions, maintaining hydrolysis of phosphodiester bonds and associated cleavage of matrix DNA as well as modulation of macrophage polarization. Neither growth of tissue cells or macrophages nor hemolysis are negatively affected by exposure to ZnO 2 @CeMOF/Br nanocatalysts at a ZnO 2 nanoparticle over CeMOFs weight ratio ≤ 1.2, up until CeMOF concentrations less than at least 180 μg/mL. Under biosafe, low-turnover catalytic conditions, irrigation of infected wounds in diabetic mice with ZnO 2 @CeMOF/Br nanocatalysts (90 μg/mL) results in 100% survival, fast recovery of healthy body temperature and weight, lower numbers of CFUs in blood and wound and organ tissues, and macrophage polarization toward an M1-like phenotype, demonstrating potential of ZnO 2 @CeMOF/Br nanocatalysts for non-antibiotic-based infection control.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced Nanomaterials in Catalysis · Nanoplatforms for cancer theranostics · Neutrophil, Myeloperoxidase and Oxidative Mechanisms

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute of Functional Nano and Soft Materials, Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices

Soochow University

Department of Biomaterials and Biomedical Technology, University of Groningen and University Medical Center Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands

Department of Orthodontics, University of Groningen and University Medical Center of Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands

Funding

Collaborative Innovation Center of Suzhou Nano Science and Technology · National Key Research and Development Program of China · Universitair Medisch Centrum Groningen · National Natural Science Foundation of China · Higher Education Discipline Innovation Project · Joint International Research Laboratory of Carbon-Based Materials and Devices · Suzhou Key Laboratory of nanotechnology and Biomedicine

References (70)

Show source-provided references
1. 10.1038/nrd397510.1038/nrd3975 ↗
2. 10.1126/scitranslmed.abo779310.1126/scitranslmed.abo7793 ↗
3. 10.1016/j.xinn.2023.10050310.1016/j.xinn.2023.100503 ↗
4. 10.1038/nri.2016.9010.1038/nri.2016.90 ↗
5. 10.3109/09513590.2013.85253110.3109/09513590.2013.852531 ↗
6. 10.1017/S002966511200015810.1017/S0029665112000158 ↗
7. 10.1146/annurev-physiol-022516-03433910.1146/annurev-physiol-022516-034339 ↗
8. 10.3390/ijms1906180110.3390/ijms19061801 ↗
9. 10.1038/s41577-020-0391-510.1038/s41577-020-0391-5 ↗
10. 10.1016/j.jaci.2009.12.98010.1016/j.jaci.2009.12.980 ↗
11. 10.1126/sciadv.ade544610.1126/sciadv.ade5446 ↗
12. 10.1186/s40824-023-00405-710.1186/s40824-023-00405-7 ↗
13. 10.1038/s41580-020-0230-310.1038/s41580-020-0230-3 ↗
14. 10.3390/antiox1107139410.3390/antiox11071394 ↗
15. 10.1021/acsnano.0c0525510.1021/acsnano.0c05255 ↗
16. 10.1021/acsnano.2c0900810.1021/acsnano.2c09008 ↗
17. 10.1016/j.jinorgbio.2015.02.01410.1016/j.jinorgbio.2015.02.014 ↗
18. 10.1007/s00018-020-03591-y10.1007/s00018-020-03591-y ↗
19. 10.1038/nri178510.1038/nri1785 ↗
20. 10.1021/acsnano.0c0148610.1021/acsnano.0c01486 ↗
21. 10.1016/j.jtv.2024.03.01510.1016/j.jtv.2024.03.015 ↗
22. 10.1039/C4CC10346G10.1039/C4CC10346G ↗
23. 10.1007/s00430-012-0277-710.1007/s00430-012-0277-7 ↗
24. 10.1021/jacs.0c0120410.1021/jacs.0c01204 ↗
25. 10.1002/adfm.20190549310.1002/adfm.201905493 ↗
26. 10.1021/acsnano.7b0749610.1021/acsnano.7b07496 ↗
27. 10.3390/antibiotics1001004910.3390/antibiotics10010049 ↗
28. 10.1016/j.cej.2023.14222210.1016/j.cej.2023.142222 ↗
29. 10.1021/acsami.3c1299710.1021/acsami.3c12997 ↗
30. 10.1021/acsnano.1c1104010.1021/acsnano.1c11040 ↗
31. 10.1007/s00403-006-0713-x10.1007/s00403-006-0713-x ↗
32. Tsukada K. · Wounds · 1992 · 4 · 16
33. 10.6026/97320630021006210.6026/973206300210062 ↗
34. 10.1371/journal.pone.003221910.1371/journal.pone.0032219 ↗
35. 10.2174/187428580110501002110.2174/1874285801105010021 ↗
36. Kamali E. · BMC Microbiol. · 2021 · 21 · 34710.1186/s12866-021-02411-y ↗
37. De Furio M. · Appl. Environ. Microb. · 2017 · 83 · e01345-1710.1128/AEM.01345-17 ↗
38. 10.1007/BF0156982610.1007/BF01569826 ↗
39. 10.1038/s41579-018-0019-y10.1038/s41579-018-0019-y ↗
40. 10.3109/1040841X.2013.84163910.3109/1040841X.2013.841639 ↗
41. 10.1016/j.copbio.2014.12.00210.1016/j.copbio.2014.12.002 ↗
42. 10.1016/j.ccr.2021.21417010.1016/j.ccr.2021.214170 ↗
43. 10.1371/journal.pcbi.100100010.1371/journal.pcbi.1001000 ↗
44. 10.3390/foods703004210.3390/foods7030042 ↗
45. 10.1093/clinchem/24.9.154510.1093/clinchem/24.9.1545 ↗
46. 10.1016/j.cej.2023.14824610.1016/j.cej.2023.148246 ↗
47. 10.1016/j.jmst.2021.02.00710.1016/j.jmst.2021.02.007 ↗
48. 10.1089/dna.2009.101110.1089/dna.2009.1011 ↗
49. 10.1016/j.cej.2022.13961910.1016/j.cej.2022.139619 ↗
50. 10.3109/17435390.2010.55069610.3109/17435390.2010.550696 ↗
51. 10.3389/fmicb.2018.0256710.3389/fmicb.2018.02567 ↗
52. 10.1002/bab.163110.1002/bab.1631 ↗
53. 10.1016/j.ecoenv.2020.11063910.1016/j.ecoenv.2020.110639 ↗
54. 10.1021/acsami.3c0192810.1021/acsami.3c01928 ↗
55. 10.1038/s41598-018-29121-210.1038/s41598-018-29121-2 ↗
56. 10.1021/acs.biomac.2c0082310.1021/acs.biomac.2c00823 ↗
57. 10.1039/D1TB02615A10.1039/D1TB02615A ↗
58. 10.3389/fimmu.2023.110086910.3389/fimmu.2023.1100869 ↗
59. 10.1016/S0021-9150(03)00287-910.1016/S0021-9150(03)00287-9 ↗
60. 10.1093/intimm/dxv06310.1093/intimm/dxv063 ↗
61. 10.7150/ijms.1380010.7150/ijms.13800 ↗
62. 10.1002/smll.20220492810.1002/smll.202204928 ↗
63. 10.1111/lam.1267410.1111/lam.12674 ↗
64. 10.2166/wh.2022.06110.2166/wh.2022.061 ↗
65. 10.1016/j.watres.2013.08.03010.1016/j.watres.2013.08.030 ↗
66. 10.1021/acsnano.2c0296610.1021/acsnano.2c02966 ↗
67. 10.1021/cs300526410.1021/cs3005264 ↗
68. 10.1080/14789450.2019.163027510.1080/14789450.2019.1630275 ↗
69. A new Clinical Use of Ferumoxytol nanoparticles: An Antibiofilm Treatment; University of Pennsylvania, August 28, 2024.https://clinicaltrials.gov/study/NCT06110494?cond=NCT06110494&rank=1.
70. 10.7150/thno.3983110.7150/thno.39831 ↗